Core Viewpoint - Coherus BioSciences, Inc. is set to release its fourth quarter and full year 2024 financial results on March 10, 2025, followed by a conference call to discuss these results and provide a business update [1]. Financial Results Announcement - The financial results will be released after market close on March 10, 2025 [1]. - A conference call and webcast will begin at 5:00 p.m. ET on the same day [2]. Conference Call Details - Participants must pre-register to receive dial-in information and a personal PIN for the live call [2]. - A live and archived webcast will be available on the Coherus website after the conference call [3]. - Attendees are advised to dial in 15 minutes early for a timely connection [3]. Company Overview - Coherus is a commercial-stage biopharmaceutical company focused on innovative immunotherapies for cancer treatment [5]. - The company markets LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor, and is developing a robust immuno-oncology pipeline [5]. Immuno-Oncology Pipeline - Coherus' pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses against tumors [6]. - Casdozokitug, an IL-27 antagonistic antibody, is currently in three clinical studies, including a Phase 1/2 study for advanced solid tumors [6]. - CHS-114, a selective anti-CCR8 antibody, is in a Phase 1 study for advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC) [6].

Core Insights - Coherus BioSciences, Inc. will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on March 4, 2025 [1] - The presentation is scheduled for 11:50 a.m. Eastern time and will be accessible via a live audio webcast [1] - A replay of the presentation will be available on the Coherus investor website for approximately 90 days [1] Company Information - Coherus BioSciences, Inc. is listed on NASDAQ under the ticker CHRS [1] - The company has provided contact information for investor relations, specifically Jodi Sievers, VP of Investor Relations & Corporate Communications [2]

Core Insights - Coherus BioSciences announced final data from a Phase 2 trial of casdozokitug in combination with atezolizumab and bevacizumab for treating unresectable hepatocellular carcinoma (HCC), showing a complete response rate of 17.2% and an overall response rate of 38% [1][2][4] Group 1: Clinical Trial Results - The Phase 2 trial demonstrated an increase in overall response rate from an initially reported 27% to 38%, with complete responses rising from 10.3% to 17.2% [2][5] - The trial involved 30 treatment-naïve patients, with a primary endpoint focused on safety and tolerability, and secondary endpoints including progression-free survival (PFS) and overall response rate (ORR) [5][6] - The triplet combination of casdozokitug, atezolizumab, and bevacizumab showed promising antitumor activity and an acceptable safety profile, consistent with known adverse event profiles of the individual drugs [6][7] Group 2: Future Developments - Coherus has initiated a new randomized Phase 2 trial evaluating casdozokitug in combination with toripalimab and bevacizumab, aimed at further assessing safety and efficacy [3][8] - The new trial is expected to enroll up to 72 patients and will compare two biologically active doses of casdozokitug [8] Group 3: Mechanism and Significance - Casdozokitug is a first-in-class antibody targeting IL-27, which plays a role in suppressing anti-tumor immune responses, making it a novel target for cancer treatment [3][11] - The data from the trial support the ongoing development of IL-27 as a promising target for advanced solid tumors, addressing significant unmet needs in the treatment landscape for liver cancer [4][10]

Core Points - Coherus BioSciences, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 5:15 p.m. Pacific Time [1] - The presentation will include a Q&A session and will be accessible via Webcast on the Coherus website [1] - The Webcast will be available for replay until February 10, 2025 [1]

Core Insights - Coherus BioSciences has initiated a randomized Phase 2 study evaluating the combination of casdozokitug, toripalimab, and bevacizumab in patients with liver cancer, specifically unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) [1][2][3] Company Developments - The Phase 2 study (NCT06679985) aims to assess the safety, efficacy, and dosing of the triplet combination in first-line HCC patients, with an expected enrollment of up to 72 patients [2][3] - Casdozokitug is a first-in-class IL-27 antagonist that has shown promising responses in combination with standard care therapies [2][3] - The upcoming ASCO GI Annual Meeting will feature a poster presentation of final clinical and biomarker data from the Phase 2 trial [1][4] Clinical Data and Efficacy - Previous studies, such as the Phase 3 HEPATORCH study, demonstrated that toripalimab combined with bevacizumab significantly outperformed sorafenib monotherapy, with an objective response rate of 25.3% compared to 6.1% and median overall survival of 20 months versus 14.5 months [3][4] - The combination of toripalimab and bevacizumab was well tolerated, with no new safety signals identified, supporting its use as a first-line treatment option for advanced HCC [3][4] Market Context - Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers and is the third leading cause of cancer-related deaths globally, with an estimated 41,630 new cases and 29,840 deaths in the U.S. in 2024 [4][5] - The treatment landscape for liver cancer is evolving with the introduction of immunotherapy combinations, which are expected to improve outcomes for patients [5]

Company Overview - Coherus BioSciences (NASDAQ: CHRS) is focused on immunotherapy and aims to expand the market for their PD-1 antibody while developing novel treatment options for solid tumors [1] Recent Performance - The company has recently experienced a recovery, indicating potential positive momentum in its operations and market position [1]

Core Viewpoint - Coherus BioSciences, Inc. has entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of its Udenyca franchise for up to $558.4 million, which includes an upfront payment of $483.4 million and potential milestone payments of $75 million [1][2]. Group 1: Financial Implications - The transaction proceeds will be used to fully repay $230 million in existing convertible notes due April 2026 and $49.1 million to buy out certain royalty obligations related to Udenyca [2]. - The deal is expected to close by the end of Q1 2025 [3]. Group 2: Strategic Focus - The divestiture aligns with the company's strategy to concentrate R&D and commercial resources on its innovative immuno-oncology portfolio [2]. - Coherus plans to advance its immuno-oncology portfolio in combination with Loqtorzi, a next-generation PD-1, which is marketed in the U.S. for two indications [3]. Group 3: Future Development Plans - Additional partnerships evaluating Loqtorzi with other cancer agents are planned for 2025 [4]. - Coherus intends to initiate a Phase 2 trial of casdozokitug/toripalimab/bevacizumab in first-line hepatocellular carcinoma in Q4 2024, with final data from a Phase 2 trial in Q1 2025 [4]. - The company plans to report Phase 1 monotherapy biopsy data and combination safety data in head and neck squamous cell carcinoma in 1H 2025 [4]. Group 4: Recent Performance - Following the announcement, CHRS stock increased by 41.6%, reaching $1.94 [6].

Financial Data and Key Metrics Changes - Coherus BioSciences reported total net product revenue of $70.6 million for Q3 2024, a 21% increase compared to Q2 2024 [22] - UDENYCA revenue reached $66 million in Q3 2024, reflecting a 30% increase from Q2 2024 and a 100% increase from Q3 2023 [10][22] - LOQTORZI net revenue was $5.8 million in Q3 2024, a 54% increase quarter-over-quarter [22] - The net loss for Q3 2024 was $10.8 million, or $0.09 per diluted share, compared to a net loss of $39.6 million, or $0.41 per diluted share for the same period in 2023 [54] Business Line Data and Key Metrics Changes - UDENYCA maintained its number 2 position in the market with nearly 30% market share, despite a temporary supply interruption [10][29] - LOQTORZI sales grew 54% quarter-over-quarter, indicating strong execution against the launch plan [16][22] - The UDENYCA franchise saw a 30% increase in revenue from Q2 to Q3 2024, driven by a 54% increase in demand for the on-body presentation [27] Market Data and Key Metrics Changes - UDENYCA's market share in the pegfilgrastim class is approximately 28% [29] - The estimated market for nasopharyngeal carcinoma (NPC) is valued at $150 million to $200 million, with expectations for LOQTORZI to achieve a dominant market share position [25] Company Strategy and Development Direction - The company is focused on a four-part strategy to deliver long-term shareholder value: driving top-line growth, controlling operating expenses, advancing the pipeline, and improving capital structure [9][20] - Coherus is expanding its supply chain by bringing an additional labeling and packaging CMO online, aiming to double its capacity to over one million UDENYCA units annually [15] - The company is advancing a pipeline of innovative immune-oncology drug candidates, targeting large patient populations and high unmet needs [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of UDENYCA sales post-supply interruption, with expectations for robust replenishment in the supply chain [65] - The management team highlighted the importance of customer relationships and the innovative features of UDENYCA in driving future demand [68] - The company anticipates substantial market share increases for UDENYCA in 2025 and beyond [15] Other Important Information - The company is reducing the high end of its expected range of combined R&D and SG&A expenses for 2024 to $250 million to $260 million [56] - Cash equivalents and investments in marketable securities were $97.7 million as of September 30, 2024, down from $117.7 million at year-end [55] Q&A Session Summary Question: What are the expectations for the casdo and tori trial in second line lung cancer? - Management noted that they are encouraged by previous data sets showing partial responses in PDL1 refractory subjects and are proceeding with a stage design for the ongoing study [60][61] Question: Can you clarify when UDENYCA will be available in the commercial channel again? - Management expects sales to resume in late November to early December, with robust replenishment anticipated [65][66] Question: What is the expected response rate benchmark for docetaxel in the casdozo trial? - The baseline docetaxel overall response rate is around 12%, and the company aims for an increment over that in their ongoing study [73] Question: Will there be any impact on customer purchasing volumes due to the supply disruption? - Management indicated that there have been no indications from customers about purchasing in less volume as they diversify their supply chains [80]

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 90%. A quarter ago, it was expected that this drug developer would post a loss of $0.21 per share when it actually produced a loss of $0.14, delivering a surprise of 33.33%.Over the last four quarters, the company has ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact ...